Treatment	treatment	O	O
of	of	O	O
previously	previously	O	O
treated	treated	O	O
metastatic	metastatic	O	O
breast	breast	O	B_disease
cancer	cancer	O	S_disease
by	by	O	O
mitoxantrone	mitoxantrone	S_chemical	O
and	and	O	O
48-hour	48-hour	O	O
continuous	continuous	O	O
infusion	infusion	O	O
of	of	O	O
high-dose	high-dose	O	O
5-FU	5-fu	S_chemical	O
and	and	O	O
leucovorin	leucovorin	O	O
(	(	O	O
MFL	mfl	O	O
):	):	O	O
low	low	O	O
palliative	palliative	O	O
benefit	benefit	O	O
and	and	O	O
high	high	O	O
treatment-related	treatment-related	O	O
toxicity	toxicity	O	S_disease
.	.	O	O

For	for	O	O
previously	previously	O	O
treated	treated	O	O
advanced	advanced	O	O
breast	breast	O	B_disease
cancer	cancer	O	S_disease
,	,	O	O
there	there	O	O
is	is	O	O
no	no	O	O
standard	standard	O	O
second-line	second-line	O	O
therapy	therapy	O	O
.	.	O	O

Combination	combination	O	O
chemotherapy	chemotherapy	O	O
with	with	O	O
mitoxantrone	mitoxantrone	S_chemical	O
,	,	O	O
high-dose	high-dose	O	O
5-fluorouracil	5-fluorouracil	S_chemical	O
(	(	O	O
5-FU	5-fu	S_chemical	O
)	)	O	O
and	and	O	O
leucovorin	leucovorin	O	O
(	(	O	O
MFL	mfl	O	O
regimen	regimen	O	O
)	)	O	O
had	had	O	O
been	been	O	O
reported	reported	O	O
as	as	O	O
an	an	O	O
effective	effective	O	O
and	and	O	O
well	well	O	O
tolerated	tolerated	O	O
regimen	regimen	O	O
.	.	O	O

From	from	O	O
October	october	O	O
1993	1993	O	O
to	to	O	O
November	november	O	O
1995	1995	O	O
,	,	O	O
we	we	O	O
treated	treated	O	O
13	13	O	O
patients	patients	O	O
with	with	O	O
previously	previously	O	O
chemotherapy-treated	chemotherapy-treated	O	O
metastatic	metastatic	O	O
breast	breast	O	B_disease
cancer	cancer	O	S_disease
by	by	O	O
mitoxantrone	mitoxantrone	S_chemical	O
,	,	O	O
12	12	O	O
mg/m2	mg/m2	O	O
,	,	O	O
on	on	O	O
day	day	O	O
1	1	O	O
and	and	O	O
continuous	continuous	O	O
infusion	infusion	O	O
of	of	O	O
5-FU	5-fu	S_chemical	O
,	,	O	O
3000	3000	O	O
mg/m2	mg/m2	O	O
,	,	O	O
together	together	O	O
with	with	O	O
leucovorin	leucovorin	O	O
,	,	O	O
300	300	O	O
mg/m2	mg/m2	O	O
,	,	O	O
for	for	O	O
48	48	O	O
h	h	S_chemical	O
from	from	O	O
day	day	O	O
1	1	O	O
to	to	O	O
2	2	O	O
.	.	O	O

Each	each	O	O
course	course	O	O
of	of	O	O
chemotherapy	chemotherapy	O	O
was	was	O	O
given	given	O	O
every	every	O	O
4	4	O	O
weeks	weeks	O	O
.	.	O	O

Most	most	O	O
of	of	O	O
these	these	O	O
patients	patients	O	O
had	had	O	O
more	more	O	O
than	than	O	O
two	two	O	O
metastatic	metastatic	O	O
sites	sites	O	O
,	,	O	O
with	with	O	O
lung	lung	O	O
metastasis	metastasis	O	O
predominant	predominant	O	O
.	.	O	O

Seven	seven	O	O
patients	patients	O	O
had	had	O	O
been	been	O	O
treated	treated	O	O
with	with	O	O
anthracycline	anthracycline	S_chemical	O
.	.	O	O

Seven	seven	O	O
patients	patients	O	O
had	had	O	O
previously	previously	O	O
received	received	O	O
radiotherapy	radiotherapy	O	O
and	and	O	O
seven	seven	O	O
had	had	O	O
received	received	O	O
hormone	hormone	O	O
therapy	therapy	O	O
.	.	O	O

Median	median	O	O
number	number	O	O
of	of	O	O
courses	courses	O	O
of	of	O	O
MFL	mfl	O	O
regimen	regimen	O	O
given	given	O	O
was	was	O	O
six	six	O	O
and	and	O	O
the	the	O	O
median	median	O	O
cumulative	cumulative	O	O
dose	dose	O	O
of	of	O	O
mitoxantrone	mitoxantrone	S_chemical	O
was	was	O	O
68.35	68.35	O	O
mg/m2	mg/m2	O	O
.	.	O	O

One	one	O	O
patient	patient	O	O
had	had	O	O
complete	complete	O	O
response	response	O	O
,	,	O	O
seven	seven	O	O
had	had	O	O
stable	stable	O	O
disease	disease	O	O
,	,	O	O
none	none	O	O
had	had	O	O
partial	partial	O	O
response	response	O	O
and	and	O	O
five	five	O	O
had	had	O	O
progressive	progressive	O	O
disease	disease	O	O
.	.	O	O

The	the	O	O
overall	overall	O	O
objective	objective	O	O
response	response	O	O
rate	rate	O	O
was	was	O	O
7.6	7.6	O	O
%	%	O	O
.	.	O	O

The	the	O	O
median	median	O	O
follow-up	follow-up	O	O
period	period	O	O
was	was	O	O
14	14	O	O
months	months	O	O
.	.	O	O

Median	median	O	O
survival	survival	O	O
was	was	O	O
16	16	O	O
months	months	O	O
.	.	O	O

Median	median	O	O
progression-free	progression-free	O	O
survival	survival	O	O
was	was	O	O
5	5	O	O
months	months	O	O
.	.	O	O

A	a	O	O
complete	complete	O	O
responder	responder	O	O
had	had	O	O
relapse-free	relapse-free	O	O
survival	survival	O	O
up	up	O	O
to	to	O	O
17	17	O	O
months	months	O	O
.	.	O	O

Major	major	O	O
toxicities	toxicities	O	S_disease
were	were	O	O
cardiotoxicity	cardiotoxicity	O	S_disease
and	and	O	O
leukopenia	leukopenia	O	S_disease
.	.	O	O

Eight	eight	O	O
patients	patients	O	O
were	were	O	O
dead	dead	O	O
in	in	O	O
the	the	O	O
last	last	O	O
follow-up	follow-up	O	O
;	;	O	O
two	two	O	O
of	of	O	O
them	them	O	O
died	died	O	O
of	of	O	O
treatment-related	treatment-related	O	O
toxicity	toxicity	O	S_disease
.	.	O	O

The	the	O	O
MFL	mfl	O	O
regimen	regimen	O	O
achieves	achieves	O	O
little	little	O	O
palliative	palliative	O	O
benefit	benefit	O	O
and	and	O	O
induces	induces	O	O
severe	severe	O	O
toxicity	toxicity	O	S_disease
at	at	O	O
a	a	O	O
fairly	fairly	O	O
high	high	O	O
rate	rate	O	O
.	.	O	O

Administration	administration	O	O
of	of	O	O
this	this	O	O
regimen	regimen	O	O
to	to	O	O
breast	breast	O	B_disease
cancer	cancer	O	S_disease
patients	patients	O	O
who	who	O	O
have	have	O	O
been	been	O	O
treated	treated	O	O
by	by	O	O
chemotherapy	chemotherapy	O	O
and	and	O	O
those	those	O	O
with	with	O	O
impaired	impaired	O	O
heart	heart	O	O
function	function	O	O
requires	requires	O	O
careful	careful	O	O
attention	attention	O	O
.	.	O	O

